Stock Taper
SCREENER COMPARE ANY 2 STOCKS
REPL
REPLIMUNE GROUP, INC.
NASDAQ
$15.50
▼ DOWN 0.64% (-0.10)

KEY STATISTICS

Market Cap$1.30 B
52w High$16.15
52w Low$1.50
Dividend Yield—
Frequency—
P/E-4.92
Volume2.39M
Shares Out.84.03M

COMPANY

LEADERSHIP

Sushil Patel
CHIEF EXECUTIVE
Sushil Patel

COMPENSATION 2026

Salary$700,000
Stock Awards$3,376,003
Incentive Plan Pay$315,000
All Other Comp.$6,654
Total$5,845,982

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 20, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
465

PRICE TARGET

Target High$20.00
Target Low$17.00
Target Median$19.00
Target Consensus$18.67

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$1.00M
NOV
5
THU

PRICE

$15.50 ▼ DOWN 0.64% (−$0.10)
$15.45$15.60$15.759:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM15.50

About Replimune Group, Inc.

https://www.replimune.com ↗

Replimune Group, Inc. is a biotech company developing oncolytic immuno-gene therapies, including RP1, RP2, and RP3, to activate the immune system against cancer, with several candidates in clinical trials.

INDUSTRY

Biotechnology

A PRODUCT REPLIMUNE GROUP, INC. IS KNOWN FOR

RP1 (vusolimogene oderparepvec)
RP1 (vusolimogene oderparepvec)

RP1, Replimune's lead genetically modified herpes simplex virus-based oncolytic immunotherapy, aims to directly kill cancer cells and stimulate immune responses, primarily targeting skin cancers like cutaneous squamous cell carcinoma and anti-PD1 ...

COMPETITORS

COMPETITOR
CADL COMPARE
CGON COMPARE
GNLX COMPARE
IOVA COMPARE
ONCY COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
95
LISTED HERE
21
RANKED BY POSITION SIZE
XBI
0.38% · 2.9M
XSU.TO
0.04% · 2.0M
VTI
0.00% · 2.0M
PTH
2.45% · 443.0K
SCHA
0.02% · 353.7K
FESM
0.05% · 220.0K
DFAS
0.02% · 168.5K
CANC
0.79% · 108.4K
LABU
0.26% · 106.5K
XRSG.L
0.04% · 72.5K
CN
CNCR
3.54% · 47.2K
LFSC
0.56% · 45.4K
RSSL
0.04% · 37.8K
BBC
1.05% · 35.3K
GSSC
0.03% · 23.1K
MEDX
1.03% · 11.4K
AVSC
0.00% · 9.4K
SGRW
0.19% · 3.7K
URTY
0.02% · 3.2K
VETS
0.02% · 1.8K
RESM
0.04% · 150

INSTITUTIONAL OWNERSHIP

SHARES OWNED
86.92%
HOLDERS
303
TOP 12 OF 303 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
11.0M sh · $122.27M
Blackrock, Inc.
9.0M sh · $99.17M
Price T Rowe Associates Inc /Md/
8.3M sh · $34.8M
Rtw Investments, LP
7.4M sh · $82.05M
Ridgeback Capital Investments L.P.
7.3M sh · $80.93M
Blackrock Inc.
4.7M sh · $42.42M
Goldman Sachs Group Inc
4.5M sh · $50.27M
State Street Corp
4.4M sh · $49.15M
Suvretta Capital Management, LLC
4.4M sh · $48.6M
Fcpm Iii Services B.V.
4.2M sh · $17.42M
Boxer Capital Management, LLC
4.0M sh · $44.09M
Vanguard Group Inc
3.8M sh · $36.7M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
Astley-Sparke Philip
Sale · 50.0K shares
2026-08-20
★
OFFICER: CHIEF FINANCIAL OFFICER
Hill Emily Luisa
Sale · 9.3K shares
2026-08-17
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Patel Sushil
Sale · 39.3K shares
2026-08-10
★
OFFICER: CHIEF FINANCIAL OFFICER
Hill Emily Luisa
Sale · 11.4K shares
2026-08-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 3
OUTPERFORM 2
HOLD 1
SELL 1
MARKET PERFORM 1
8 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT Wedbush OUTPERFORM Leerink Partners OUTPERFORM Cantor Fitzgerald OVERWEIGHT Jefferies HOLD HC Wainwright & Co. SELL Piper Sandler OVERWEIGHT BMO Capital MARKET PERFORM

SECTORS PEERS

PEERPRICE
IOVA$8.01COMPARE
MBX$63.00COMPARE
VIR$10.83COMPARE
AVBP$30.17COMPARE
MGTX$13.82COMPARE
PRME$3.61COMPARE
VALN$6.43COMPARE
ARVN$9.18COMPARE